News | January 21, 2026
Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
The AI Nurse Companion, designed as a language-first learning platform, allows students to gain real-world German language proficiency through immersive practice
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Subscribe To Our Newsletter & Stay Updated
